iotaSciences, a provider of single-cell biology handling solutions, will unveil its next-generation Single-Cell Cloning Platform XT at the Cell 2024 conference in London.
 
The new platform, an upgrade to its predecessor, leverages iotaSciences’ proprietary fluid-shaping technology to automate single-cell isolation, culture, and transfer. This enhanced automation increases throughput and speed while maintaining high-quality results.
 
A key feature of the platform is the integration of SCAI technology, which enables automated identification and documentation of monoclonal cultures. This ensures reliable and verifiable results, making the platform suitable for various applications, including stem cell research, gene editing, cell line development, and reporter cell line generation.
 
iotaSciences’ Chief Product Officer, Dr. Alexander Feuerborn, said: “We are highly excited about the availability of our new Single-Cell Cloning Platform XT, which addresses our customers’ need to receive a full plate of verified monoclonal cultures with reliable, high-quality, results in a documented manner. In addition, we are very proud to debut our newly developed SCAI technology in this next-generation single-cell handling solution.”
 
“This product advancement is further proof of our strategy to position iotaSciences as a leader in the rapidly evolving field of single-cell biology handling by bringing pioneering novel solutions to this space,” added Dr. Michael Lutz, CEO of iotaSciences. “Such solutions are key to R&D workflows related to Cell and Gene Therapy (CGT) and other applications, and represent a multimillion-dollar market potential in the coming years.”